In biotech's early days, companies thought they could hedge their long-term bets by relatively inexpensive and much shorter-term plays in diagnostics. But finding diagnostics with enough value proved difficult. Now biotechs are at it again, focusing on the diagnostic implications of pharmacogenomics, the science of linking drug efficacy to genes, which can be used to sort out which patients will benefit from particular drugs.
You may also be interested in...
The Scientific Committee on Consumer Safety will consider available safety data for prostaglandin analogs isopropyl cloprostenate, ethyl tafluprostamide and others with known use in eyelash-growth cosmetic products in the EU. Currently, the substances are not restricted in cosmetic products.
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.